Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

1.

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, Maitra A, Wang H, Tian W, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2015 May 29;107(8). pii: djv132. doi: 10.1093/jnci/djv132. Print 2015 Aug.

PMID:
26025324
2.

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry.

Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara DR, Hanash SM, Kim K, Fiehn O.

Metabolites. 2015 Apr 9;5(2):192-210. doi: 10.3390/metabo5020192.

3.

Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.

Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H, McFerrin L, Selamat SA, Yang C, Kroh EM, Garg KS, Behrens C, Gazdar AF, Laird-Offringa IA, Tewari M, Wistuba II, Thiery JP, Hanash SM.

Cancer Res. 2015 May 1;75(9):1789-800. doi: 10.1158/0008-5472.CAN-14-2535. Epub 2015 Mar 5.

PMID:
25744723
4.

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.

Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.

5.

Modeling putative therapeutic implications of exosome exchange between tumor and immune cells.

Lu M, Huang B, Hanash SM, Onuchic JN, Ben-Jacob E.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4165-74. doi: 10.1073/pnas.1416745111. Epub 2014 Sep 22.

6.

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets.

Taguchi A, Taylor AD, Rodriguez J, Celiktaş M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM.

Cancer Res. 2014 Sep 1;74(17):4694-705. doi: 10.1158/0008-5472.CAN-13-3725. Epub 2014 Jun 26.

7.

Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer.

Mao J, Ladd J, Gad E, Rastetter L, Johnson MM, Marzbani E, Childs JS, Lu H, Dang Y, Broussard E, Stanton SE, Hanash SM, Disis ML.

J Transl Med. 2014 May 10;12:121. doi: 10.1186/1479-5876-12-121.

8.

Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.

Prentice RL, Zhao S, Johnson M, Aragaki A, Hsia J, Jackson RD, Rossouw JE, Manson JE, Hanash SM.

Genome Med. 2013 Dec 27;5(12):112. doi: 10.1186/gm517. eCollection 2013.

9.

Mouse to human blood-based cancer biomarker discovery strategies.

Hanash SM, Taguchi A.

Cold Spring Harb Protoc. 2014 Feb 1;2014(2):144-9. doi: 10.1101/pdb.top078808. Review.

PMID:
24173314
10.

A novel soluble form of Tim-3 associated with severe graft-versus-host disease.

Hansen JA, Hanash SM, Tabellini L, Baik C, Lawler RL, Grogan BM, Storer B, Chin A, Johnson M, Wong CH, Zhang Q, Martin PJ, McDonald GB.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1323-30. doi: 10.1016/j.bbmt.2013.06.011. Epub 2013 Jun 17.

11.

Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.

Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM.

PLoS One. 2013 Jun 10;8(6):e67054. doi: 10.1371/journal.pone.0067054. Print 2013.

12.

Enrichment strategies in glycomics-based lung cancer biomarker development.

Ruhaak LR, Nguyen UT, Stroble C, Taylor SL, Taguchi A, Hanash SM, Lebrilla CB, Kim K, Miyamoto S.

Proteomics Clin Appl. 2013 Oct;7(9-10):664-76. doi: 10.1002/prca.201200131. Epub 2013 Aug 6.

13.

Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line.

Wu SL, Taylor AD, Lu Q, Hanash SM, Im H, Snyder M, Hancock WS.

Mol Cell Proteomics. 2013 May;12(5):1239-49. doi: 10.1074/mcp.M112.024554. Epub 2013 Jan 31.

14.

Imaging a functional tumorigenic biomarker in the transformed epithelium.

LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93-8. doi: 10.1073/pnas.1218694110. Epub 2012 Dec 17.

15.

Unleashing the power of proteomics to develop blood-based cancer markers.

Taguchi A, Hanash SM.

Clin Chem. 2013 Jan;59(1):119-26. doi: 10.1373/clinchem.2012.184572. Epub 2012 Oct 24. Review.

16.

Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.

Thomé CH, dos Santos GA, Ferreira GA, Scheucher PS, Izumi C, Leopoldino AM, Simão AM, Ciancaglini P, de Oliveira KT, Chin A, Hanash SM, Falcão RP, Rego EM, Greene LJ, Faça VM.

Mol Cell Proteomics. 2012 Dec;11(12):1898-912. doi: 10.1074/mcp.M112.019661. Epub 2012 Sep 22.

17.

Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Li CI, Mirus JE, Zhang Y, Ramirez AB, Ladd JJ, Prentice RL, McIntosh MW, Hanash SM, Lampe PD.

Breast Cancer Res Treat. 2012 Sep;135(2):611-8. doi: 10.1007/s10549-012-2204-4. Epub 2012 Aug 19.

18.

Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.

Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice R, Hanash SM, Disis ML.

Cancer Prev Res (Phila). 2012 Aug;5(8):1036-43. doi: 10.1158/1940-6207.CAPR-11-0558. Epub 2012 Jun 19.

19.

Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.

Amon LM, Pitteri SJ, Li CI, McIntosh M, Ladd JJ, Disis M, Porter P, Wong CH, Zhang Q, Lampe P, Prentice RL, Hanash SM.

Cancer Res. 2012 Apr 15;72(8):1935-42. doi: 10.1158/0008-5472.CAN-11-3266. Epub 2012 Feb 24.

20.

Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.

Press JZ, Reyes M, Pitteri SJ, Pennil C, Garcia R, Goff BA, Hanash SM, Swisher EM.

Int J Gynecol Cancer. 2012 May;22(4):546-52. doi: 10.1097/IGC.0b013e318241d9b9.

PMID:
22315094
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk